Loading...
Market
How will Sanofi's tolebrutinib phase 3 trial results compare to teriflunomide by December 31, 2024?
2
Resolution / Starting Odds
Significantly better • 25%
Moderately better • 25%
Similar • 25%
Worse • 25%
Sanofi's trial data publications and peer-reviewed journals
Story
Sanofi's Tolebrutinib Delays Disability Progression in MS by 31% in Phase 3 Trial
Sep 20, 2024, 09:55 AM
Sanofi has announced that its experimental drug, tolebrutinib, has demonstrated a significant 31% delay in the progression of disability for patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in a phase 3 trial. This development provides hope for patients suffering from this progressive form of multiple sclerosis, for which there is currently no effective treatment. The French pharmaceutical company plans to file for approval of tolebrutinib later this year. Despite the promising results, the drug showed higher new Gd-enhancing T1 lesions compared to teriflunomide in the GEMINI-1/2 trials. The results were presented at the ECTRIMS 2024 conference.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Successful • 50%
Unsuccessful • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%